Preimplantation Genetic Testing Market to Surpass USD 2294.8 million by 2035 on IVF and Genetic Health Advancements

The preimplantation genetic testing (PGT) market is entering a transformative decade. Estimated at USD 934.5 million in 2025, it is projected to climb to USD 2294.8 million by 2035, reflecting a healthy compound annual growth rate (CAGR) of 9.4%. This steady momentum demonstrates how medical innovation, patient awareness, and the rising adoption of assisted reproductive technologies (ART) are converging to redefine reproductive healthcare worldwide.

The Expanding Role of Genetic Testing in Fertility Care

Preimplantation genetic testing plays a critical role in enhancing the success of in vitro fertilization (IVF) procedures. By analyzing embryos before implantation, clinicians can identify genetic abnormalities, reduce the risk of hereditary disorders, and improve the chances of delivering a healthy baby.

Among application types, aneuploidy screening will lead the market in 2025, accounting for 26.7% of revenue. This reflects its importance in identifying chromosomal abnormalities that often result in failed pregnancies or miscarriages. Advanced sequencing and microarray technologies now make it possible to detect these abnormalities with unprecedented precision, giving patients and physicians actionable insights at critical decision-making moments.

Beyond aneuploidy, growing use cases such as single gene disorder screening, HLA typing, and chromosomal aberration testing are strengthening PGT's value as a comprehensive reproductive solution. Fertility specialists increasingly view genetic testing not as an optional add-on but as a core element of precision reproductive medicine.

The Market Dynamics Driving Growth

The global PGT market is supported by several key dynamics. The rise of genetic disorders among prospective parents, combined with delayed pregnancies and higher maternal ages, is fueling demand for reliable embryo testing. Assisted reproductive technologies are no longer limited to select geographies or demographics; they are expanding globally, especially in Asia-Pacific and Europe, creating fertile ground for PGT adoption.

Advancements in molecular diagnostics, next-generation sequencing (NGS), and high-throughput platforms are improving both accuracy and efficiency. Automated systems and laboratory information management integration are minimizing errors and enhancing workflow in fertility clinics and diagnostic labs.

Regulatory support and standardized protocols are further strengthening confidence in PGT services. Patients increasingly recognize the value of genetic testing in safeguarding family health, while clinicians are empowered with tools that deliver faster, more reliable results.

Segment Insights: Reagents, Clinics, and Precision Testing

From a product perspective, reagents are expected to dominate the market in 2025, holding 33.4% of revenue. High-quality reagents are indispensable for DNA amplification, sequencing, and chromosomal assessment, enabling laboratories to achieve reliable and reproducible results. Continuous innovation in reagent formulations is lowering error rates and enhancing compatibility with automated testing platforms, driving broader adoption across fertility clinics and maternity centers.

Among end users, fertility clinics and maternity centers will hold the largest share at 38.9% in 2025. Their dominance reflects the surge in IVF services globally, coupled with rising awareness among patients about the benefits of early genetic screening. Investments in laboratory infrastructure and automation are equipping these centers with capabilities once limited to large hospitals and research institutions, bringing advanced testing closer to patients.

Regional Landscape: Asia Rising, Europe Steady, North America Reliable

Geographically, the PGT market exhibits strong global momentum. China is expected to lead with the highest CAGR of 12.7% through 2035, driven by the expansion of domestic IVF centers and rising healthcare spending. India follows at 11.8%, supported by a growing fertility services industry and increasing awareness of genetic testing options among younger populations.

Germany and France remain pillars of the European market, with CAGRs of 10.8% and 9.9% respectively, showcasing strong adoption in advanced fertility clinics supported by regulatory frameworks. The United Kingdom, with steady 8.9% growth, reflects both maturity and continuous demand for precision healthcare.

In North America, the United States will account for significant value, growing from USD 345.5 million in 2025 to USD 745.2 million by 2035. Despite a slightly lower CAGR of 8.0%, the U.S. remains a vital hub for innovation, with leading companies investing heavily in molecular diagnostics and personalized reproductive medicine.

Brazil, with a CAGR of 7.1%, highlights the gradual expansion of IVF and genetic testing services in Latin America, driven by increasing middle-class access to advanced healthcare solutions.

Competitive Landscape: Leaders, Innovators, and New Entrants

The PGT market features an impressive roster of global leaders and rising innovators. Illumina, Agilent Technologies, Thermo Fisher Scientific, and Natera are at the forefront, leveraging their expertise in sequencing, reagents, and precision diagnostics. Vitrolife Group (Igenomix), Medicover Genetics, and Virtus Health are expanding their service footprints, bringing integrated fertility and genetic testing solutions to new markets.

Meanwhile, companies like Fulgent Genetics, Revvity, Takara Bio, and Genea BIOMEDX are broadening their technological platforms, offering flexibility and scalability to fertility clinics worldwide. Varinos and RGI are carving niches with specialized offerings, reinforcing the growing diversity of players contributing to market expansion.

Established players continue to safeguard their dominance through global supply chains, regulatory compliance, and trusted partnerships with fertility networks. At the same time, newer entrants and regional manufacturers are investing in laboratory automation, cost-effective reagent development, and patient-centered services to win market share. This healthy mix of stability and innovation ensures a competitive and vibrant marketplace.

Purchase this Report for USD 5,000 Only | Get an Exclusive Discount Instantly! https://www.futuremarketinsights.com/checkout/2590

Everything You Need-within Your Budget. Request a Special Price Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-2590

Browse the Complete Report: https://www.futuremarketinsights.com/reports/preimplantation-genetic-testing-market

Related Reports:

DNA Synthesis Market: https://www.futuremarketinsights.com/reports/dna-synthesis-market

Point Of Care Blood Testing Devices Market: https://www.futuremarketinsights.com/reports/point-of-care-blood-testing-devices-market

Pathology Imaging Systems Market: https://www.futuremarketinsights.com/reports/pathology-imaging-systems-market

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

This release was published on openPR.